



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/501,030	08/12/2004	Norbert E. Fusenig	0471-0286PUS1	3120

2292 7590 01/22/2010
BIRCH STEWART KOLASCH & BIRCH
PO BOX 747
FALLS CHURCH, VA 22040-0747

EXAMINER

HENRY, MICHAEL C

ART UNIT	PAPER NUMBER
----------	--------------

1623

NOTIFICATION DATE	DELIVERY MODE
-------------------	---------------

01/22/2010

ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

mailroom@bskb.com

Office Action Summary	Application No. 10/501,030	Applicant(s) FUSENIG ET AL.	
	Examiner MICHAEL C. HENRY	Art Unit 1623	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 06 November 2009.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 18, 22-27, 30 and 36 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 18, 22-27, 30 and 36 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|---|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

The following office action is a responsive to the Amendment filed, 11/06/09.

The amendment filed 11/06/09 affects the application, 10/501,030 as follows:

1. Claim 31-35 and 37-38 have been canceled. Applicant's argument have overcome the rejection of the prior office action mailed 08/16/09. However, a new ground(s) rejection is set forth herein below.
2. The responsive to applicants' amendments and arguments is contained herein below.

Claims 18, 22-27, 30 and 36 are pending in the application

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 18, 22-27, 30 and 36 are rejected under 35 U.S.C. 103(a) as being unpatentable over Berkeley et al. (Surgery, gynecology & obstetrics, (1983 Mar) Vol. 156, No. 3, pp. 319-22) in view of Pressato et al. (WO 97/07833).

In claim 18 applicant claims "A method for the treatment and care of primary and secondary tumors by inhibiting angiogenesis which comprises applying at the tumor site a biomaterial comprised of a benzyl ester of hyaluronic acid wherein said hyaluronic acid is a total benzyl ester of hyaluronic acid, wherein said hyaluronic acid is 100% benzyl esterified and wherein said biomaterial inhibits angiogenic processes related to vascularization by granulation tissue forming over the biomaterial and wherein said biomaterial is in the form of at least one

Art Unit: 1623

member selected from the group consisting of a non-woven felt, sponge, microsphere, film and membrane.” Claims 22-27, 30 and 31 are drawn to said method wherein the hyaluronic acid is in association with other natural, synthetic and/or semisynthetic biopolymers, pharmacologically active substance, specific pharmacological active substance and specific form of application to tumor site and wherein the vascularisation and specific tumor cell invasion is specifically limited.

Berkeley et al. disclose that myomectomy (wherein uterine fibroids or fibroids tumors are surgically removed from the uterus) itself may decrease fertility of women, probably on the basis of adhesion formation (see abstract).

The difference between applicant's claimed method and the method disclosed by Berkeley et al. is that Berkeley et al. do not recite the use of a specific ester (i.e., benzyl ester) of hyaluronic acid.

Pressato et al. disclose a biomaterial comprised of benzyl ester of hyaluronic acid in the form of gels, membranes, woven tissues or meshes and nonwoven tissues that can be used to prevent surgical adhesion (page 5, lines 20-26). This suggests that benzyl ester of hyaluronic acid can be in the form of gels, membranes, woven tissues or meshes and nonwoven tissues (of a biomaterial) that can be administered directly to the treated site (page 5, lines 20-26). Furthermore, Pressato et al. disclose that their benzyl ester of hyaluronic acid can be 75-100% esterified (see claim 1). In addition, Pressato et al. disclose that biodegradable and non-biodegradable materials such as polymers in their composition.

It would have been obvious to one having ordinary skill in the art, at the time the claimed invention was made, in view of Berkeley et al. and Pressato et al., to treat tumors such as fibroid

Art Unit: 1623

tumors with a composition (e.g., a biomaterial) comprising a benzyl ester of hyaluronic acid in order to prevent surgical adhesion resulting from myomectomy and to consequently prevent a decrease in fertility of women, since Pressato et al. disclose that benzyl ester of hyaluronic acid can be prepared in the form of gels, membranes, woven tissues or meshes and nonwoven tissues (of a biomaterial) and can be administered directly to a treated site to prevent surgical adhesion.

One having ordinary skill in the art would have been motivated in view of Berkeley et al. and Pressato et al., to treat tumors such as fibroid tumors with a composition (e.g., a biomaterial) comprising a benzyl ester of hyaluronic acid in order to prevent surgical adhesion resulting from myomectomy and to consequently prevent a decrease in fertility of women, since Pressato et al. disclose that benzyl ester of hyaluronic acid can be prepared in the form of gels, membranes, woven tissues or meshes and nonwoven tissues (of a biomaterial) and can be administered directly to a treated site to prevent surgical adhesion. It should be noted that it is obvious to further include or use pharmaceutically active substance such as antitumor or cancer drugs to treat said tumors. It should also be noted that the formation of granulation tissue is considered an inherent effect of the ester of hyaluronic acid which results due to the inhibition or regression of angiogenesis.

Response to Arguments

Applicant's arguments with respect to claims 18, 22-27, 30 and 36 have been considered but are moot in view of the new ground(s) of rejection.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michael C. Henry whose telephone number is 571-272-0652.

Art Unit: 1623

The examiner can normally be reached on 8.30am-5pm; Mon-Fri. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Shaojia A. Jiang can be reached on 571-272-0627. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Michael C. Henry
January 16, 2010.

/Shaojia Anna Jiang/
Supervisory Patent Examiner
Art Unit 1623